Research ArticleAccepted Article
Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review
Bernice L. Sim, Beatrice Z. Sim, Matthew Tunbridge, David F.L. Liew and Philip C. Robinson
The Journal of Rheumatology September 2022, jrheum.220524; DOI: https://doi.org/10.3899/jrheum.220524
Bernice L. Sim
PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom; Faculty of Medicine, The University of Queensland, Herston, QLD, Australia; Department of Rheumatology and Department of Clinical Pharmacology and Therapeutics, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, VIC, Australia; Department of Rheumatology, Royal Brisbane & Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia. Corresponding Author: Associate Professor Philip Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women's Hospital, Herston, Queensland 4006, Australia.
Beatrice Z. Sim
PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom; Faculty of Medicine, The University of Queensland, Herston, QLD, Australia; Department of Rheumatology and Department of Clinical Pharmacology and Therapeutics, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, VIC, Australia; Department of Rheumatology, Royal Brisbane & Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia. Corresponding Author: Associate Professor Philip Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women's Hospital, Herston, Queensland 4006, Australia.
Matthew Tunbridge
PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom; Faculty of Medicine, The University of Queensland, Herston, QLD, Australia; Department of Rheumatology and Department of Clinical Pharmacology and Therapeutics, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, VIC, Australia; Department of Rheumatology, Royal Brisbane & Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia. Corresponding Author: Associate Professor Philip Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women's Hospital, Herston, Queensland 4006, Australia.
David F.L. Liew
PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom; Faculty of Medicine, The University of Queensland, Herston, QLD, Australia; Department of Rheumatology and Department of Clinical Pharmacology and Therapeutics, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, VIC, Australia; Department of Rheumatology, Royal Brisbane & Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia. Corresponding Author: Associate Professor Philip Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women's Hospital, Herston, Queensland 4006, Australia.
Philip C. Robinson
PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. St. George's Hospital Medical School, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom; Faculty of Medicine, The University of Queensland, Herston, QLD, Australia; Department of Rheumatology and Department of Clinical Pharmacology and Therapeutics, Austin Health, 145 Studley Rd, Heidelberg VIC 3084, Australia; Department of Medicine, University of Melbourne, Parkville, VIC, Australia; Department of Rheumatology, Royal Brisbane & Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia. Corresponding Author: Associate Professor Philip Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women's Hospital, Herston, Queensland 4006, Australia.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review
Bernice L. Sim, Beatrice Z. Sim, Matthew Tunbridge, David F.L. Liew, Philip C. Robinson
The Journal of Rheumatology Sep 2022, jrheum.220524; DOI: 10.3899/jrheum.220524